- Edward C. Cooper, M.D. Ph.D., Principal Investigator
Baylor College of Medicine, Houston, Texas, United States
- John J Millichap M.D., Co-Investigator
Lurie Children’s Hospital, Chicago, Ill., United States
- Tammy Tsuchida M.D. Ph.D., Co-Investigator
Children’s National Medical Center, Washington DC, United States
This research is supported by The Jack Pribaz Foundation, KCNQ2 Cure Alliance, and FamilieSCN2A Foundation. These foundations were formed by parents of children affected by early-onset genetic epilepsy. The funders want to shorten the time families often wait before obtaining a specific genetic diagnosis, and encourage future development of new targeted treatments. Invitae is providing reduced cost testing and results reporting to ERGENT as a collaboration with the research team, family groups, and study participants. Baylor College of Medicine’s Department of Neurology has supported the planning and development of ERGENT.
Edward C. Cooper is a consultant to Knopp Biosciences and Xenon Pharmaceuticals, which are interested in developing products related to early onset genetic epilepsy. The terms of these arrangements have been reviewed and approved by Baylor College of Medicine in accordance with its policy on Financial Conflicts of Interest in Research. John J. Millichap has conflict of interest to declare. Tammy Tsuchida has no conflicts of interest to declare.